골관절염 치료제 시장 규모, 점유율, 성장 분석 : 약물 유형별, 해부 부위별, 투여 경로별, 판매 채널별, 최종 용도별, 지역별 - 업계 예측(2026-2033년)

Osteoarthritis Therapeutics Market size was valued at USD 10.16 Billion in 2024 and is poised to grow from USD 10.86 Billion in 2025 to USD 18.51 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The osteoarthritis therapeutics market is experiencing significant growth driven by the rising prevalence of the condition, particularly among the aging population. A substantial portion of the American population suffers from osteoarthritis, underscoring the urgent need for effective treatment options. This demand is further amplified by advancements in disease understanding and the development of innovative therapies. Women are at heightened risk due to factors such as musculoskeletal abnormalities and hormonal changes, as well as a higher prevalence of obesity, which compounds the incidence of osteoarthritis. The complex nature of osteoarthritis, characterized by thick and avascular tissue, presents management challenges; however, advancements in intra-articular drug delivery systems and a focus on disease-modifying medications hold promise for enhancing treatment efficacy and fostering ongoing research and development in the field.

Top-down and bottom-up approaches were used to estimate and validate the size of the Osteoarthritis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Osteoarthritis Therapeutics Market Segments Analysis

Global Osteoarthritis Therapeutics Market is segmented by Drug Type, Anatomy, Route of Administration, Sales Channel, End Use and region. Based on Drug Type, the market is segmented into Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics, Corticosteroids and Others. Based on Anatomy, the market is segmented into Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis and Others. Based on Route of Administration, the market is segmented into Parenteral Route, Topical Route and Oral Route. Based on Sales Channel, the market is segmented into Prescription Drugs and Over-the-Counter Drugs. Based on End Use, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Osteoarthritis Therapeutics Market

The osteoarthritis therapeutics market is poised for significant growth, primarily fueled by the increasing prevalence of joint degenerative diseases among the aging population, particularly in developed regions like North America and Europe. As individuals age, the likelihood of experiencing osteoarthritis rises, creating a heightened need for effective treatment options. This demographic trend is driving both demand and innovation in therapeutic solutions, as healthcare providers and pharmaceutical companies seek to address the challenges associated with managing this chronic condition. Consequently, the market is expected to expand, reflecting the urgent need for advanced therapeutics tailored to older adults suffering from osteoarthritis.

Restraints in the Osteoarthritis Therapeutics Market

The potential side effects linked to traditional osteoarthritis treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, pose a significant limitation in the market. Long-term usage of these medications can result in serious complications, such as gastrointestinal disorders and cardiovascular problems. Consequently, the adverse effects associated with these therapies deter patients from utilizing them, prompting a search for safer alternatives. This shift in patient preference ultimately hampers the widespread adoption of conventional osteoarthritis treatments, highlighting the need for safer and more effective options in managing this prevalent condition.

Market Trends of the Osteoarthritis Therapeutics Market

The osteoarthritis therapeutics market is witnessing a significant trend towards the adoption of minimally invasive treatments, such as viscosupplementation and biologic injections. These therapies offer effective pain relief and enhance joint functionality, all while requiring less recovery time compared to traditional surgical interventions. As both patients and healthcare providers increasingly recognize the benefits of these options-namely improved outcomes and reduced downtime-minimally invasive alternatives are gaining traction. This growing preference marks a shift in treatment paradigms, encouraging innovation and investment in less invasive solutions, ultimately reshaping the landscape of osteoarthritis management and treatment approaches.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Osteoarthritis Therapeutics Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Viscosupplementation Agents
• Nonsteroidal Anti-inflammatory Drugs
  • Naproxen
  • Aspirin
  • Diclofenac
  • Ibuprofen
  • Celecoxib
  • Meloxicam
  • Piroxicam
  • Ketoprofen
  • Other NSAIDs
• Analgesics
  • Duloxetine
  • Acetaminophen
• Corticosteroids
• Others

Global Osteoarthritis Therapeutics Market Size by Anatomy & CAGR (2026-2033)

• Market Overview
• Knee Osteoarthritis
• Hip Osteoarthritis
• Hand Osteoarthritis
• Others

Global Osteoarthritis Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Parenteral Route
  • Hyaluronic Acid Injections
  • Corticosteroid Injections
  • Platelet-rich Plasma (PRP) Injections
  • Placental Tissue Matrix (PTM) Injections
  • Acetylsalicylic Acid (ASA) Injections
  • Others
• Topical Route
• Oral Route

Global Osteoarthritis Therapeutics Market Size by Sales Channel & CAGR (2026-2033)

• Market Overview
• Prescription Drugs
• Over-the-Counter Drugs

Global Osteoarthritis Therapeutics Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Osteoarthritis Therapeutics Market Size & CAGR (2026-2033)

• North America (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • US
  • Canada
• Europe (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Flexion Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seikagaku Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TissueGene, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anika Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ampio Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioDelivery Sciences International, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bone Therapeutics SA (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kolon TissueGene, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Centrexion Therapeutics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kiniksa Pharmaceuticals, Ltd. (Bermuda)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations